An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'.
Warunya Arunotayanun, Jeffrey W Dalley, Xi-Ping Huang, Vincent Setola, Ric Treble, Leslie Iversen, Bryan L Roth, Simon Gibbons
Bioorganic & medicinal chemistry letters June 1, 2013 DOI: 10.1016/j.bmcl.2013.03.066 via PubMed
Summary
AI-generated from the abstractTwo widely marketed novel psychoactive drugs, alpha-methyl-tryptamine and 5-methoxy-N,N-diallyl-tryptamine, were analyzed for their chemical structure and binding to serotonin receptor subtypes. These tryptamine-derived compounds, sold without restriction, can cause psychosis and hallucinations that may lead to injury or death. The study elucidates their structures and receptor binding profiles, providing insight into their pharmacological actions.
Study at a glance
| Characteristics | Experimental study Peer reviewed |
|---|---|
| Citations | 41 |
| Key finding | The structures and serotonin receptor binding profiles of alpha-methyl-tryptamine and 5-methoxy-N,N-diallyl-tryptamine were determined. |
Abstract
Novel Psychoactive Drugs (NPD) can be sold without restriction and are often synthetic analogues of controlled drugs. The tryptamines are an important class of NPD as they bind to the various serotonin (5-HT) receptor subtypes and cause psychosis and hallucinations that can lead to injury or death through misadventure. Here we report on the structure elucidation and receptor binding profiles of two widely marketed tryptamine-derived NPDs, namely alpha-methyl-tryptamine and 5-methoxy-N,N-diallyl-tryptamine.